NuGEN has been a valued partner in the development and commercialization of Afirma^® Thyroid FNA Analysis. NuGEN’s sample preparation technology is a critical component in addressing the challenges of extracting genomic information from small, fine needle aspirate biopsies. Their dependable supply, quality and excellent customer service provides us with the assurance we need in pioneering the development of novel molecular diagnostic tests.

My colleagues and I are using high-throughput sequencing methods to study age-related diseases and have employed the Ovation^® Target Enrichment System for targeted sequencing and identification of genetic variants. In conjunction with this method, we have utilized the Ovation^® Target Enrichment Data Processing Application for BaseSpace to perform data analysis. We found the application to be a valuable tool for eliminating bottlenecks associated with basic data processing. The application aids our studies by streamlining data analysis and accelerating the understanding of the functional impact of genetic variants on the underlying processes of age-related diseases.

A lung adenocarcinoma tumor that was determined to have an ALK rearrangement by clinical SNaPshot Genotyping (multiplex PCR assay) was grown as a patient-derived xenograft model. Using NuGEN’s fusion detection workflow, the tumor was confirmed to have an EML4-ALK fusion after two passages in mice

The Ovation Fusion Detection BaseSpace Application in conjunction with NuGEN’s comprehensive fusion panel provides a simple start to finish workflow.  This solution helps us to not only identify clinically actionable fusions but also to perform basic research to study how other fusions may be relevant to cancer progression and prognosis in a single assay.